• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.环磷酰胺用于干细胞动员可克服来那度胺治疗对多发性骨髓瘤干细胞采集的抑制作用。
Biol Blood Marrow Transplant. 2008 Jul;14(7):795-8. doi: 10.1016/j.bbmt.2008.04.008.
2
Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen.多发性骨髓瘤患者的干细胞采集：诱导治疗和动员方案的影响。
Bone Marrow Transplant. 2011 Jan;46(1):59-63. doi: 10.1038/bmt.2010.63. Epub 2010 May 3.
3
Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.新型诱导疗法治疗多发性骨髓瘤患者的外周血造血干细胞动员：中剂量与低剂量环磷酰胺和粒细胞集落刺激因子。
Biol Blood Marrow Transplant. 2012 Jul;18(7):1128-35. doi: 10.1016/j.bbmt.2012.01.005. Epub 2012 Jan 14.
4
Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.环磷酰胺联合粒细胞集落刺激因子用于多发性骨髓瘤患者造血干细胞动员
J Clin Apher. 2016 Oct;31(5):423-8. doi: 10.1002/jca.21421. Epub 2015 Sep 5.
5
Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma.新诊断多发性骨髓瘤患者自体干细胞移植前基于环磷酰胺的造血干细胞动员
J Clin Apher. 2015 Jun;30(3):176-82. doi: 10.1002/jca.21360. Epub 2014 Oct 8.
6
Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.在新型治疗时代，使用普乐沙福和粒细胞集落刺激因子（G-CSF）动员多发性骨髓瘤患者的外周血干细胞，与使用低剂量环磷酰胺和G-CSF进行动员相比，具有更高的疗效，但成本显著更高。
J Clin Apher. 2013 Oct;28(5):359-67. doi: 10.1002/jca.21280. Epub 2013 Jun 14.
7
Peripheral blood stem cell mobilisation following bortezomib, lenalidomide and dexamethasone induction for multiple myeloma: a real-world single-centre experience.硼替佐米、来那度胺和地塞米松诱导多发性骨髓瘤后的外周血造血干细胞动员：真实世界单中心经验。
Intern Med J. 2024 Jan;54(1):108-114. doi: 10.1111/imj.16170. Epub 2023 Jul 23.
8
Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma.长春瑞滨联合粒细胞集落刺激因子对多发性骨髓瘤患者CD34+造血祖细胞动员的疗效
Biol Blood Marrow Transplant. 2015 Jan;21(1):74-80. doi: 10.1016/j.bbmt.2014.09.020. Epub 2014 Sep 30.
9
Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.多发性骨髓瘤患者在先前使用来那度胺后，非格司亭诱导的干细胞动员受损。
Biol Blood Marrow Transplant. 2009 Jun;15(6):718-23. doi: 10.1016/j.bbmt.2009.02.011. Epub 2009 Apr 8.
10
Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone.在接受包含硼替佐米、环磷酰胺和地塞米松的统一诱导方案治疗的多发性骨髓瘤患者中，不同干细胞动员方式后的植入情况比较。
Ann Hematol. 2017 Mar;96(3):461-467. doi: 10.1007/s00277-016-2897-2. Epub 2016 Dec 24.

引用本文的文献

1
Moving Beyond G-CSF Mobilization-Learning From a 15-Year Experience of Different Stem Cell Mobilization Regimens in Multiple Myeloma.超越粒细胞集落刺激因子动员——从多发性骨髓瘤不同干细胞动员方案的15年经验中学习
Cancer Med. 2025 Jul;14(14):e71068. doi: 10.1002/cam4.71068.
2
Effect of prior lenalidomide or daratumumab exposure on hematopoietic stem cell collection and reconstitution in multiple myeloma.来那度胺或达雷妥尤单抗预先暴露对多发性骨髓瘤患者造血干细胞采集和重建的影响。
Ann Hematol. 2024 Oct;103(10):3839-3853. doi: 10.1007/s00277-024-05683-2. Epub 2024 Mar 6.
3
Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis.两种干细胞动员方案（环磷酰胺联合 G-CSF 或单独 G-CSF）在多发性骨髓瘤中的疗效、安全性和生存结局比较：一项荟萃分析。
Ann Hematol. 2021 Feb;100(2):563-573. doi: 10.1007/s00277-020-04376-w. Epub 2021 Jan 6.
4
Successful hematopoietic stem-cell mobilization with plerixafor plus granulocyte-colony stimulating factor in multiple myeloma patients treated with pomalidomide.培洛利珠单抗联合粒细胞集落刺激因子成功动员多发性骨髓瘤患者造血干细胞。
Int J Hematol. 2019 Jul;110(1):115-118. doi: 10.1007/s12185-019-02622-0. Epub 2019 Apr 13.
5
Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement.造血干细胞移植治疗多发性骨髓瘤的应用：梅奥多发性骨髓瘤分层与风险适应性治疗（mSMART）共识声明。
Bone Marrow Transplant. 2019 Mar;54(3):353-367. doi: 10.1038/s41409-018-0264-8. Epub 2018 Jul 9.
6
Improved progression-free and event-free survival in myeloma patients undergoing PBSCH receiving a cyclophosphamide + G-CSF regimen than G-CSF alone.与单独使用粒细胞集落刺激因子（G-CSF）相比，接受环磷酰胺+G-CSF方案的自体骨髓干细胞移植（PBSCH）骨髓瘤患者的无进展生存期和无事件生存期得到改善。
Int J Hematol. 2018 May;107(5):559-567. doi: 10.1007/s12185-018-2408-4. Epub 2018 Jan 31.
7
Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?多发性骨髓瘤中的外周血干细胞动员：生长因子还是化疗？
World J Transplant. 2017 Oct 24;7(5):250-259. doi: 10.5500/wjt.v7.i5.250.
8
Mobilization policy in multiple myeloma: minimum target or law of redundancy? Two different approaches by the two sides of the Atlantic Ocean.多发性骨髓瘤的动员策略：最低目标还是冗余法则？大西洋两岸的两种不同方法。
Bone Marrow Transplant. 2016 Mar;51(3):348-50. doi: 10.1038/bmt.2015.317. Epub 2015 Dec 21.
9
Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.多发性骨髓瘤，2016年第2版：肿瘤学临床实践指南
J Natl Compr Canc Netw. 2015 Nov;13(11):1398-435. doi: 10.6004/jnccn.2015.0167.
10
A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma.一项关于在多发性骨髓瘤中基于来那度胺诱导后使用环磷酰胺+粒细胞集落刺激因子（G-CSF）或单独使用G-CSF进行干细胞动员的随机II期研究。
Bone Marrow Transplant. 2016 Mar;51(3):372-6. doi: 10.1038/bmt.2015.236. Epub 2015 Oct 5.

本文引用的文献

1
Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma.在骨髓瘤患者中，来那度胺诱导治疗后干细胞动员受损。
Leukemia. 2008 Jun;22(6):1282-4. doi: 10.1038/sj.leu.2405100. Epub 2008 Jan 24.
2
Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients.来那度胺治疗对既往未经治疗的多发性骨髓瘤患者外周血干细胞动员的影响。
Leukemia. 2008 Jun;22(6):1280-1; author reply 1281-2. doi: 10.1038/sj.leu.2405035. Epub 2007 Nov 22.
3
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.来那度胺联合地塞米松治疗北美复发多发性骨髓瘤
N Engl J Med. 2007 Nov 22;357(21):2133-42. doi: 10.1056/NEJMoa070596.
4
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.来那度胺联合地塞米松治疗复发或难治性多发性骨髓瘤。
N Engl J Med. 2007 Nov 22;357(21):2123-32. doi: 10.1056/NEJMoa070594.
5
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.BiRD（克拉仙[克拉霉素]/瑞复美[来那度胺]/地塞米松）联合疗法在初治有症状的多发性骨髓瘤患者中产生了较高的完全缓解率和总缓解率。
Blood. 2008 Feb 1;111(3):1101-9. doi: 10.1182/blood-2007-05-090258. Epub 2007 Nov 7.
6
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma.来那度胺联合地塞米松治疗新诊断骨髓瘤的治疗反应长期结果、疾病进展时间及生存率
Mayo Clin Proc. 2007 Oct;82(10):1179-84. doi: 10.4065/82.10.1179.
7
Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial.单剂量自体干细胞移植后使用沙利度胺维持治疗在多发性骨髓瘤中优于双剂量自体移植：一项多中心随机临床试验的结果
Blood. 2008 Feb 15;111(4):1805-10. doi: 10.1182/blood-2007-07-101212. Epub 2007 Sep 17.
8
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.来那度胺所致骨髓抑制与肾功能不全相关：接受一线来那度胺和地塞米松治疗的初治患者不良事件评估
Br J Haematol. 2007 Sep;138(5):640-3. doi: 10.1111/j.1365-2141.2007.06698.x.
9
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.来那度胺治疗对新诊断骨髓瘤患者外周血干细胞移植后干细胞动员和植入的影响。
Leukemia. 2007 Sep;21(9):2035-42. doi: 10.1038/sj.leu.2404801. Epub 2007 Jun 21.
10
Stem cell transplant for first relapse from the multiple myeloma research foundation.多发性骨髓瘤研究基金会开展的首次复发干细胞移植。
Oncology (Williston Park). 2006 Dec;20(14):1818, 1820-1, 1825-6.

环磷酰胺用于干细胞动员可克服来那度胺治疗对多发性骨髓瘤干细胞采集的抑制作用。

Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.

作者信息

Mark Tomer, Stern Jessica, Furst Jessica R, Jayabalan David, Zafar Faiza, LaRow April, Pearse Roger N, Harpel John, Shore Tsiporah, Schuster Michael W, Leonard John P, Christos Paul J, Coleman Morton, Niesvizky Ruben

机构信息

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York Presbyterian Hospital-Cornell Medical Center, New York, New York 10021, USA.

出版信息

Biol Blood Marrow Transplant. 2008 Jul;14(7):795-8. doi: 10.1016/j.bbmt.2008.04.008.

DOI:10.1016/j.bbmt.2008.04.008
PMID:18541199
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3626097/
Abstract

A total of 28 treatment-naïve patients with stage II or III multiple myeloma (MM) were treated with the combination of clarithromycin, lenalidomide, and dexamethasone (BiRD). Stem cells were collected following granulocyte-colony stimulating factor (G-CSF) or cyclophosphamide (Cy) plus G-CSF mobilization at maximum response. Sufficient stem cells for 2 autologous stem cell transplants were collected from all patients mobilized with Cy plus G-CSF, versus 33% mobilized with G-CSF alone (P < .0001). The duration of prior lenalidomide therapy did not correlate with success of stem cell harvests (P = .91). In conclusion, Cy can be added to G-CSF for stem cell mobilization to successfully overcome the suppressive effect of prior treatment with lenalidomide.

摘要

共有28例初治的II期或III期多发性骨髓瘤（MM）患者接受了克拉霉素、来那度胺和地塞米松联合治疗（BiRD）。在最大反应时，采用粒细胞集落刺激因子（G-CSF）或环磷酰胺（Cy）加G-CSF动员后采集干细胞。所有接受Cy加G-CSF动员的患者均采集到足够进行2次自体干细胞移植的干细胞，而仅接受G-CSF动员的患者这一比例为33%（P < .0001）。来那度胺先前治疗的持续时间与干细胞采集的成功率无关（P = .91）。总之，Cy可添加到G-CSF中用于干细胞动员，以成功克服先前使用来那度胺治疗的抑制作用。